Loading...
Taxotere as a Treatment for Ovarian Epithelial Carcinoma
Hollfelder, Gabrielle LaRochelle, Sophie Neumann, Bernd
Hollfelder, Gabrielle
LaRochelle, Sophie
Neumann, Bernd
An error occurred retrieving the object's statistics
Citations
Altmetric:
Journal Title
Keywords
Readers/Advisors
Journal Title
Term and Year
Publication Date
2017
Book Title
Publication Volume
Publication Issue
Publication Begin
Publication End
Number of pages
Files
Loading...
Taxotere.4.pdf
Adobe PDF, 405.73 KB
Research Projects
Organizational Units
Journal Issue
Abstract
Citation
DOI
Description
Epithelial ovarian cancer accounts for 90% of ovarian cancers, is the most lethal gynecological cancer, and the fifth-most common cause of cancer-related deaths in women in the United States(6). In 2016, there were an esitmated 22,280 new cases in the U.S. and the overall survival rate at 5 years is 46.2%(3). About 10% of cases are heriditary (4). Clinical trials have shown that the efficacy of more traditional platinum-based drugs are increased when combined with a taxane-based drug. Docetaxel, commercially Taxotere, is a taxane that has been in use since the mid-1990s and is used to treat many forms of cancer including ovarian but also; breast, lung, head and neck, gastric and prostrate carcinomas. Taxotere is derived from the needles of the European Yew tree (Taxus baccata) by a semisynthetic process(1)and like other taxane-based drugs, binds to microtubules during mitosis leading to apoptosis and cell death(2).